- Home
- IMMX vs RFL Comparison
IMMX vs RFL Comparison
Compare IMMX & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- RFL
- Stock Information
- Founded
- IMMX 2014
- RFL 2017
- Country
- IMMX United States
- RFL United States
- Employees
- IMMX N/A
- RFL N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- RFL Real Estate
- Sector
- IMMX Health Care
- RFL Finance
- Exchange
- IMMX Nasdaq
- RFL Nasdaq
- Market Cap
- IMMX 51.1M
- RFL 48.4M
- IPO Year
- IMMX 2021
- RFL N/A
- Fundamental
- Price
- IMMX $1.66
- RFL $2.00
- Analyst Decision
- IMMX Strong Buy
- RFL
- Analyst Count
- IMMX 1
- RFL 0
- Target Price
- IMMX $7.00
- RFL N/A
- AVG Volume (30 Days)
- IMMX 125.2K
- RFL 47.3K
- Earning Date
- IMMX 11-11-2024
- RFL 10-28-2024
- Dividend Yield
- IMMX N/A
- RFL N/A
- EPS Growth
- IMMX N/A
- RFL N/A
- EPS
- IMMX N/A
- RFL N/A
- Revenue
- IMMX N/A
- RFL $540,000.00
- Revenue This Year
- IMMX N/A
- RFL N/A
- Revenue Next Year
- IMMX $200.00
- RFL N/A
- P/E Ratio
- IMMX N/A
- RFL N/A
- Revenue Growth
- IMMX N/A
- RFL 92.86
- 52 Week Low
- IMMX $1.26
- RFL $1.29
- 52 Week High
- IMMX $7.75
- RFL $2.14
- Technical
- Relative Strength Index (RSI)
- IMMX 45.76
- RFL 74.68
- Support Level
- IMMX $1.43
- RFL $1.65
- Resistance Level
- IMMX $1.94
- RFL $1.94
- Average True Range (ATR)
- IMMX 0.13
- RFL 0.10
- MACD
- IMMX -0.01
- RFL 0.02
- Stochastic Oscillator
- IMMX 57.97
- RFL 100.00
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.